| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ICAM2 |
| Uniprot No | P13598 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-223aa |
| 氨基酸序列 | MSSFGYRTLT VALFTLICCP GSDEKVFEVH VRPKKLAVEP KGSLEVNCST TCNQPEVGGL ETSLDKILLD EQAQWKHYLV SNISHDTVLQ CHFTCSGKQE SMNSNVSVYQ PPRQVILTLQ PTLVAVGKSF TIECRVPTVE PLDSLTLFLF RGNETLHYET FGKAAPAPQE ATATFNSTAD REDGHRNFSC LAVLDLMSRG GNIFHKHSAP KMLEIYEPVS DSQ |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ICAM2重组蛋白的3篇参考文献示例(基于真实研究方向的模拟，具体文献需通过数据库验证)：
---
1. **文献名称**：*"Expression and Functional Characterization of Recombinant Soluble ICAM-2 in Leukocyte Adhesion"*
**作者**：Smith A, et al.
**摘要**：该研究通过哺乳动物表达系统(HEK293细胞)成功制备了可溶性ICAM-2重组蛋白，并证实其与淋巴细胞表面整合素LFA-1的结合能力，揭示了ICAM-2在调节免疫细胞迁移中的关键作用。
2. **文献名称**：*"Optimized Production of ICAM-2 in Escherichia coli for Structural Studies"*
**作者**：Lee JH, et al.
**摘要**：作者利用大肠杆菌表达系统优化了ICAM-2胞外域的重组表达和纯化流程，通过X射线晶体学解析其三维结构，为靶向ICAM-2的药物设计提供了结构基础。
3. **文献名称**：*"Recombinant ICAM-2 Modulates Endothelial Barrier Function in Inflammatory Models"*
**作者**：Gomez C, et al.
**摘要**：研究发现重组ICAM-2蛋白可通过抑制血管内皮细胞中炎症信号通路(如NF-κB)，减轻实验性急性肺损伤模型的血管渗漏，提示其潜在治疗价值。
---
**注**：以上文献为模拟示例，实际引用时需通过PubMed或Web of Science等平台核实具体信息。真实文献可通过关键词“recombinant ICAM-2”、“soluble ICAM-2 expression”或“ICAM-2 functional study”检索。
**Background of ICAM2 Recombinant Protein**
Intercellular Adhesion Molecule 2 (ICAM2), a member of the immunoglobulin (Ig) superfamily, is a transmembrane glycoprotein primarily expressed on endothelial cells, platelets, and certain immune cells. It plays a critical role in mediating cell-cell interactions, particularly during immune and inflammatory responses. Structurally, ICAM2 contains two extracellular Ig-like domains that bind to leukocyte function-associated antigen-1 (LFA-1. or integrin αLβ2), facilitating leukocyte adhesion, transmigration across vascular endothelium, and immune surveillance. Unlike ICAM1. which is inducible under inflammatory conditions, ICAM2 is constitutively expressed, suggesting distinct regulatory roles in homeostasis and disease.
Recombinant ICAM2 protein is engineered using molecular cloning techniques, typically expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. This purified protein retains the functional domains required for ligand binding and is widely used in research to study leukocyte-endothelial interactions, signaling pathways, and inflammatory processes. Its applications extend to in vitro and in vivo models of diseases such as atherosclerosis, cancer metastasis, and autoimmune disorders, where aberrant cell adhesion contributes to pathogenesis.
Therapeutic interest in ICAM2 lies in its potential to modulate immune responses. For instance, recombinant ICAM2 or its derivatives may inhibit excessive leukocyte infiltration in chronic inflammation or serve as targeting agents for drug delivery. Additionally, ICAM2 is explored as a biomarker in vascular diseases due to its endothelial specificity. Continued studies aim to clarify its dual roles in immune regulation and pathological progression, highlighting its relevance in both basic research and translational medicine.
×
